About August Troendle
In a 2017 interview, August Troendle, founder and CEO of Medpace, discussed the company's founding and approach to drug development. Troendle stated that he founded Medpace because he believed drug development "should be done by experts in drug development." He described Medpace as a full-service contract research organization (CRO) that focuses on internal expertise before launching into a therapeutic area, naming cardio metabolic and oncology as the largest areas by volume, while also noting expertise in areas such as AVAI and CNS.
Troendle addressed the role of company size in conducting large-scale studies, stating he does not see size as a differentiating factor for Medpace versus other companies. He noted that while the largest programs might require 50 full-time employees, Medpace has 1,700 globally, and asserted that "there are no programs that are too large." He emphasized that Medpace sticks to a full-service model and seeks companies looking for external expertise, aiming to hone its systems and processes around providing that expertise.
Source: AI-verified profile updated from August Troendle's recent appearances.
Browse all interviews →
Transcript (6 segments)
I
Interviewer0:07
Why did you found Medpace?
A
August Troendle0:07
I had worked with CROs and thought that they were good at providing staff, good staff, but poorly organized and without good process. And I thought that drug development should be done by experts in drug development, and that's what CRO should become.
I
Interviewer0:28
What are your strongest therapeutic areas?
A
August Troendle0:31
We are strong in any of the therapeutic areas in which we operate. As a model, we look towards internal expertise and capabilities before we've launched a therapeutic area. I think talk about therapeutic areas again, there are a lot of different indications. Some of them we may have a lot of experience and a lot of depth in our experts, and others not so much. But I think if you're talking about just size of the area that we operate, the largest by volume would be cardio metabolic and oncology, but we have great expertise in AI, in CNS, and elsewhere.
I
Interviewer1:09
Is the size of a CRO a factor in conducting large-scale studies?
A
August Troendle1:15
I don't really see size as being a differentiating factor, and certainly not for us versus other companies. I think the largest programs might have 50 FTEs required, and we have 1,700 globally. There are no programs that are too large. I think the model in which we operate is a bit different. We do stick to full-service and source, and we do look for companies that are looking for external expertise. We build upon that and we need to cone our systems and process around providing full-service expertise.
